AdBio partners
AdBio partners is a Paris-based venture capital firm that seeds and co-founds early-stage European life sciences startups — primarily in oncology, immunology, ophthalmology, rare disease and cardiovascular/neuroinflammatory indications — sourced from academic research institutions and technology transfer offices, and supported through management fees and carried interest.
- Company typePrivate
- Founded2016
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AdBio partners does
AdBio partners is a Paris-based venture capital firm (formerly Advent France Biotechnology, rebranded December 2021) specialized in early-stage life sciences investments across Europe. Founded in 2016 by Alain Huriez and Matthieu Coutet, the firm sources and co-founds therapeutic startups emerging from European academic research, with a particular emphasis on oncology, immunology, ophthalmology, rare diseases, and increasingly cardiovascular, renal/metabolic, and neuroinflammation indications. It does not develop proprietary technology itself; instead, it operates a thesis-driven company-creation engine combining seed and Series A capital with hands-on operational support, often taking on interim CEO or co-founder roles through its operating partners. Geographic reach spans France, Belgium, Spain, the UK, and Germany, with offices in Paris and Barcelona.
AdBio monetizes through the standard VC model: management fees on committed capital and carried interest on successful exits. It manages at least two funds — AFB Seed-Fund I (€64.75M first close, April 2017, supported by InnovFin Equity and the European Fund for Strategic Investments) and AFB Fund II (€86M first close, September 2021), with Inserm Transfert joining as an LP in Fund II. The portfolio spans 35+ companies including SparingVision, Agomab, Augustine Therapeutics, ARTHEx Biotech, Integra Therapeutics, Tenpoint Therapeutics, Astraveus, Orikine Bio, EvlaBio, and Cephagenix, and the firm co-invests with a syndicate that includes AbbVie Ventures, EIC Fund, CDTI Innvierte, Asabys Partners, Advent Life Sciences, Bpifrance, Takeda Ventures, and Invivo Capital. Strategic initiatives include the AndzonBio® Pipeline Builder platform launched with Inserm Transfert in June 2024 and collaborations extending into the UK with Cambridge Enterprise and ALBORADA.
Operationally, AdBio is led by Chairman/Managing Partner Alain Huriez and Co-founder/Managing Partner Matthieu Coutet, supported by Managing Partners Clément Bertholet (promoted 2025) and Geoffroy de Ribains (now Venture Partner since January 2025), a deep bench of Venture Partners and Principals, and a newly hired CFO (Céline de Cosnac, March 2025). The firm is regulated by the French AMF under GP 16000008, operates with 11–50 employees, and is privately held without a parent company.
AdBio partners firmographics
Firmographics- Name
- AdBio partners
- Legal name
- AdBio partners
- Website
- https://adbio.partners
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AdBio partners is a Paris-based venture capital firm that seeds and co-founds early-stage European life sciences startups — primarily in oncology, immunology, ophthalmology, rare disease and cardiovascular/neuroinflammatory indications — sourced from academic research institutions and technology transfer offices, and supported through management fees and carried interest.
- Ownership category
- akta.pro rank
AdBio partners industry classification
Industry- Product category
- Venture Capital / Life Sciences Investment
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where AdBio partners is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
AdBio partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Management Fees: VC firms typically charge management fees on committed capital during the investment period and beyond, typically 1.5-2% of assets under management.
- Carried Interest: Performance-based carried interest typically 20% of profits above the hurdle rate, aligning fund manager and investor interests in successful portfolio company exits.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
AdBio partners product offering
Product offeringCore offering
AdBio partners is a French venture capital firm that invests in and develops early-stage life sciences startups across Europe. The firm sources breakthrough therapeutic innovations from academic research and technology transfer offices, co-founds companies with scientific founders, provides seed and Series A funding, and supplies hands-on operational support including interim CEO leadership. It manages multiple funds including AFB Seed-Fund I (€64.75M) and AFB Fund II (€86M) with a portfolio of 35+ companies spanning oncology, immunology, ophthalmology, rare diseases, and other therapeutic areas.
Product overview
AdBio partners is a French venture capital firm specializing in early-stage investments in life sciences startups across Europe. Rather than offering a technology product, the company provides investment services, company-building expertise, and hands-on operational support to biotech entrepreneurs. The firm scouts promising academic innovations, co-founds companies with scientific founders, provides initial funding, and supports portfolio companies through their development journey. AdBio partners manages a diverse portfolio of biotech companies across multiple therapeutic areas including oncology, immunology, ophthalmology, and rare diseases, with portfolio companies such as Agomab Therapeutics, AndzonBio1, AndzonBio2, Arthex Biotech, Augustine Therapeutics, SparingVision, Tenpoint Therapeutics, Orikine Bio, Integra Therapeutics, and others.
Differentiator
Problem solved
Functional benefit
Products and services
- AFB Seed-Fund I AdBio partners' first seed-stage life sciences venture capital fund, providing seed and early-stage funding to European biotech startups; first closing at €64.75M.
- AFB Fund II AdBio partners' second life sciences venture capital fund, with first close at €86M, providing seed and Series A funding to European biotech startups across multiple therapeutic areas.
- AndzonBio® Pipeline Builder Companies AndzonBio® is a suite of thematic Pipeline Builder Companies launched by AdBio partners and Inserm Transfert to systematically accelerate industrial development of promising academic projects, with AndzonBio1 (cardiovascular, renal, metabolic disorders) and AndzonBio2 (neuroinflammation, expanding in 2026 to Cambridge Enterprise and ALBORADA Drug Discovery Institute).
Companies that use AdBio partners
Customer profileSegments3 records
Ideal customer profiles3 records
AdBio partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AdBio partners partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Inserm TransfertflagshipLaunched AndzonBio® initiative together with Inserm Transfert, a suite of thematic Pipeline Builder Companies to accelerate industrial development of promising academic projects in biotechnology. AndzonBio1 focuses on cardiovascular, renal and metabolic disorders; AndzonBio2 on neuroinflammation.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
AdBio partners competitors and assessment
Company assessmentDirect peers
- Sofinnova Partners: Paris-headquartered European life sciences VC with multiple strategies including early-stage seed. Comparable in target investments, geography, and therapeutic breadth, but at a significantly larger AUM scale.
- Forbion: Dutch/Netherlands-based life sciences VC investing from seed to growth across European biotech. Highly comparable in therapeutic breadth and stage focus, with substantially larger fund sizes.
- Medicxi: Swiss/European early-stage life sciences VC with a similar founder-built, asset-centric investment philosophy. Directly comparable stage focus (seed/Series A) and therapeutic-area approach.
- Andera Partners: Paris-based European life sciences VC with BioDiscovery and BioCuration strategies. Directly competes in the same French biotech seed/early-stage market and shares Paris headquarters geography.
- Kurma Partners: Paris-based European life sciences VC with early-stage and growth strategies. Competes head-to-head with AdBio for French biotech seed deals and shares the same institutional LP base.
- Atlas Venture: US/UK biotech VC specializing in seed-to-venture formation of new biotech companies. Highly comparable operating model — company-building approach with operational partners as interim executives.
- Seroba Life Sciences: European (Ireland-led) life sciences VC investing in early-stage therapeutics and medical devices. Comparable stage focus and European biotech thesis, with smaller fund size similar to AdBio's.
- BioMedPartners: Swiss/German early-stage life sciences VC investing in European biotech and medtech. Similar seed/Series A stage and therapeutic breadth; Patrick Burgermeister moved from BioMedPartners to AdBio, evidencing direct comparability.
- Seventure Partners: Paris-based European VC with a dedicated Health for Life strategy. Directly comparable French-headquartered, life-sciences-focused seed/early-stage investor with overlapping LP base.
- Newton Biocapital: Brussels-based European life sciences VC focused on early-stage therapeutic companies. Comparable European biotech seed/early-stage thesis with similar fund size and stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AdBio partners social profiles
Digital presenceAdBio partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
AdBio partners leadership team
Management profileNumber of profiles
Profiles16 records
AdBio partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AdBio partners M&A and investment
M&A and investmentM&A
Investments33 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AdBio partners
What does AdBio partners do?
AdBio partners is a French venture capital firm that invests in and develops early-stage life sciences startups across Europe. The firm sources breakthrough therapeutic innovations from academic research and technology transfer offices, co-founds companies with scientific founders, provides seed and Series A funding, and supplies hands-on operational support including interim CEO leadership. It manages multiple funds including AFB Seed-Fund I (€64.75M) and AFB Fund II (€86M) with a portfolio of 35+ companies spanning oncology, immunology, ophthalmology, rare diseases, and other therapeutic areas.
Is AdBio partners a public or private company?
AdBio partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AdBio partners founded?
AdBio partners was founded in 2016. It employs 11 to 50 people.
Where is AdBio partners based?
AdBio partners is headquartered in Paris, France, in the Europe region.
How does AdBio partners make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.
Who are AdBio partners's main competitors?
Direct peers on record are Sofinnova Partners, Forbion, Medicxi, Andera Partners, Kurma Partners, Atlas Venture, Seroba Life Sciences, BioMedPartners, Seventure Partners and Newton Biocapital.
Does AdBio partners have an API?
No public API is recorded for AdBio partners.
What industry is AdBio partners in?
AdBio partners's product category is Venture Capital / Life Sciences Investment. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 5417 and its SIC code is 6282.